Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.54 Analyst target: $47.50 Upside: 946.26%
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.